Yale IRB Greenlights Patient Recruitment for Clearmind's CMND-100 Phase I/II Trial
CMND is trading near its 52-week low of $1.16 (5.2% above the low) on elevated volume (21× avg).
Summary
Clearmind Medicine received Yale IRB approval to begin patient recruitment for Parts B and C of its CMND-100 Phase I/II trial in alcohol use disorder. This expands the trial to a fourth major site, joining Johns Hopkins and two Israeli centers, and follows positive safety data from Part A where all 24 participants completed treatment with no serious adverse events. The approval accelerates enrollment at a world-class institution and supports the company's clinical momentum. Clearmind remains a micro-cap with a going concern warning and recent dilutive financings, so this milestone is a meaningful but early-stage de-risking event. Next catalyst will be initial data from Parts B and C, though no specific readout date has been announced.
At the time of this announcement, CMND was trading at $1.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $1.16 to $524.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.